Pharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies

Bittner, 2003, Impact of solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male wistar rats, Biopharm. Drug Dispos., 24, 173, 10.1002/bdd.353 Duthaler, 2011, Evaluation of the pharmacokinetic profile of artesunate, artemether and their metabolites in sheep naturally infected with Fasciola hepatica, Vet. Parasitol Fairweather, 1999, Fasciolicides: efficacy, actions, resistance and its management, Vet. J., 158, 81, 10.1053/tvjl.1999.0377 Fairweather, 2011, Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?, Vet. Parasitol., 180, 133, 10.1016/j.vetpar.2011.05.034 FDA, 2001, FDA Guidance for Industry Bioanalytical Method Validation, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Fürst, 2012, Global burden of human food-borne trematodiasis: a systematic review and meta-analysis, Lancet Infect. Dis., 12, 210, 10.1016/S1473-3099(11)70294-8 Hotez, 2006, Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria, PLoS Med., 3, e102, 10.1371/journal.pmed.0030102 Keiser, 2005, Triclabendazole for the treatment of fascioliasis and paragonimiasis, Expert Opin. Invest. Drugs, 14, 1513, 10.1517/13543784.14.12.1513 Keiser, 2006, The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica, J. Antimicrob. Chemother., 58, 1193, 10.1093/jac/dkl408 Keiser, 2007, Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes, Trends Parasitol., 23, 555, 10.1016/j.pt.2007.07.012 Keiser, 2008, Fasciola hepatica: Surface tegumental responses to in vitro and in vivo treatment with the experimental fasciolicide OZ78, Exp. Parasitol., 119, 87, 10.1016/j.exppara.2007.12.015 Keiser, 2008, Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep, Parasitol. Res., 103, 517, 10.1007/s00436-008-0998-0 Keiser, 2009, Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica, J. Antimicrob. Chemother., 63, 543, 10.1093/jac/dkn550 Keiser, 2010, Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep, Vet. Parasitol., 173, 228, 10.1016/j.vetpar.2010.06.031 Kirchhofer, 2010, Development and validation of a liquid chromatography/mass spectrometry method for pharmacokinetic studies of OZ78, a fasciocidal drug candidate, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 878, 2770, 10.1016/j.jchromb.2010.08.020 Kirchhofer, 2011, Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproni, Acta Trop., 118, 56, 10.1016/j.actatropica.2011.02.003 Mas-Coma, 2005, Fascioliasis and other plant-borne trematode zoonoses, Int. J. Parasitol., 35, 1255, 10.1016/j.ijpara.2005.07.010 Robinson, 2009, Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases, Philos. Trans. R. Soc. Lond. B: Biol. Sci., 364, 2763, 10.1098/rstb.2009.0089 Spiegel, 2010, Which new approaches to tackling neglected tropical diseases show promise?, PLoS Med., 7, e1000255, 10.1371/journal.pmed.1000255 Vennerstrom, 2004, Identification of an antimalarial synthetic trioxolane drug development candidate, Nature, 430, 900, 10.1038/nature02779 Zhao, 2010, Structure–activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica, J. Med. Chem., 53, 4223, 10.1021/jm100226t